Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

The Battle within: AML´s p53 Strategies to Evade T-Cell Attack

Lis Winter, Lea Pawlowsky, Anetta Marcinek, Bettina Brauchle, Amelie Muth, Maryam Kazerani, Agnese Petrera, Roman Kischel, Alica Joana Emhardt, Maja Rothenberg-Thurley, Annika Maria Dufour, Karsten Spiekermann, Michael Andreeff, Naval Daver, Veit L. Buecklein, Marion Subklewe

Blood (2023) 142 (Supplement 1): 1411.

https://doi.org/10.1182/blood-2023-173826

Published: 2023

Journal Articles

Sting Activation Improves T-Cell Engaging Immunotherapy of Acute Myeloid Leukemia

Andreas Linder, Daniel Nixdorf, Niklas Kuhl, Ignazio Piseddu, TengTeng Xu, Gunnar Kuut, Simon Veth, Thomas Carell, Roman Kischel, Veit Hornung, Marion Subklewe

Blood (2023) 142 (Supplement 1): 2055.

https://doi.org/10.1182/blood-2023-179115

Published: 2023

Journal Articles

T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals

Blood (2022) 140 (10): 1104–1118.

https://doi.org/10.1182/blood.2022015956

Published: 2022

Includes: Supplemental data

Journal Articles

Treatment-Free Intervals during CD19xCD3 BiTE ® Construct-Mediated T-Cell Stimulation Induce Functional Reinvigoration and Transcriptional Reprogramming of Exhausted T Cells

Blood (2021) 138 (Supplement 1): 513.

https://doi.org/10.1182/blood-2021-150178

Published: 2021

Journal Articles

CD33 BiTE ® Construct Mediated Immunological Synapse Formation and Downstream Signaling in T Cells Is Dependent on Expression of Costimulatory Molecules on Target Cells

Anetta Marcinek, Bettina Brauchle, Gerulf Hänel, Sonja M Lacher, Nora Zieger, Roman Kischel, Michael von Bergwelt, Karsten Spiekermann, Sebastian Theurich, John R James, Veit L Buecklein, Marion Subklewe

Blood (2021) 138 (Supplement 1): 2237.

https://doi.org/10.1182/blood-2021-146488

Published: 2021

Journal Articles

Evolving Exhaustion of T Cells during the Course of the Disease in AML Can be Abrogated By CD33 BiTE ® Construct Mediated Cytotoxicity

Maryam Kazerani Pasikhani, Anetta Marcinek, Bettina Brauchle, Jonathan Jonas Taylor, Helena Domínguez Moreno, Maria Solovey, Frank Ziemann, Nora Zieger, Andrea Terrasi, Benjamin Tast, Karsten Spiekermann, Klaus H. Metzeler, Tobias Straub, Gunnar Schotta, Roman Kischel, Veit L Buecklein, Marion Subklewe

Blood (2021) 138 (Supplement 1): 1172.

https://doi.org/10.1182/blood-2021-150351

Published: 2021

Journal Articles

Treatment-Free Intervals Mitigate T-Cell Exhaustion Induced By Continuous CD19xCD3-BiTE® Construct Stimulation in Vitro

Nora Zieger, Alyssa Nicholls, Jan Wulf, Gerulf Hänel, Maryam Kazerani Pasikhani, Veit Buecklein, MD, Bettina Brauchle, Anetta Marcinek, Daniel Nixdorf, Lisa Rohrbacher, Michaela Scheurer, Roman Kischel, MD, Karsten Spiekermann, MD, Oliver Weigert, MD, Sebastian Theurich, MD, Michael von Bergwelt, MD PhD, Marion Subklewe, MD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-137421

Published: 2020

Journal Articles

Predictors of Efficacy for Blinatumomab in BCP-ALL Patients: Non-Responders Show Impaired CD19-BiTE®-Mediated Cytotoxicity in Vitro

Veit Bücklein, MD, Michaela Scheurer, Bettina Brauchle, MSc, Roman Kischel, MD, Michael von Bergwelt, Karsten Spiekermann, MD, Marion Subklewe, MD

Blood (2019) 134 (Supplement_1): 2632.

https://doi.org/10.1182/blood-2019-129057

Published: 2019

Journal Articles

Impact of p53 Knock-Down on T-Cell Proliferation and T-Cell Mediated Cytotoxicity Against AML Cell Lines Mediated By a CD33 Specific BiTE ® Antibody Construct

Lea Pawlowsky, Bettina Brauchle, MSc, Maryam Kazerani Pasikhani, Ana Ogrinc Wagner, PhD, Veit Bücklein, MD, Felix S. Lichtenegger, MD, Roman Kischel, MD, Klaus H. Metzeler, MD, Karsten Spiekermann, MD, Michael Andreeff, MD PhD, Naval G. Daver, MD, Michael von Bergwelt, Marion Subklewe, MD

Blood (2019) 134 (Supplement_1): 1265.

https://doi.org/10.1182/blood-2019-122415

Published: 2019

Journal Articles

The Ratio of Costimulatory Vs Coinhibitory Molecules on AML Cells Determines the CD33-BiTE ® Mediated T-Cell Response

Anetta Marcinek, MSc, Bettina Brauchle, MSc, Dragica Udiljak, Roman Kischel, MD, Peter Kufer, MD, Karsten Spiekermann, MD, Michael von Bergwelt, MD, Felix S. Lichtenegger, MD, Marion Subklewe, MD

Blood (2018) 132 (Supplement 1): 1349.

https://doi.org/10.1182/blood-2018-99-116297

Published: 2018

Journal Articles

Midostaurin Reduces Bite® Mediated Cytotoxicity Against Acute Myeloid Leukemia

Bettina Lindl, Christina Krupka, PhD, Tara Chapman-Arvedson, Roman Kischel, MD, Peter Kufer, MD, Sascha Haubner, MD, Felix S. Lichtenegger, MD, Thomas Koehnke, MD, Klaus H. Metzeler, MD, Nikola Konstandin, PhD, Karsten Spiekermann, Wolfgang Hiddemann, MD PhD, Marion Subklewe, MD

Blood (2017) 130 (Supplement 1): 2656.

https://doi.org/10.1182/blood.V130.Suppl_1.2656.2656

Published: 2017

Journal Articles

Generation of a Half-Life Extended Anti-CD19 BiTE ® Antibody Construct Compatible with Once-Weekly Dosing for Treatment of CD19-Positive Malignancies

Grit Lorenczewski, MS, Matthias Friedrich, Roman Kischel, MD, Christoph Dahlhoff, PhD, Jonas Anlahr, MS, Mercedesz Balazs, Dan Rock, Michael C Boyle, DVM, PhD DACVP, DABT, Rebecca Goldstein, PhD, Angela Coxon, PhD, Tara Chapman-Arvedson

Blood (2017) 130 (Supplement 1): 2815.

https://doi.org/10.1182/blood.V130.Suppl_1.2815.2815

Published: 2017

Journal Articles

CD33/CD3-Bispecific T-Cell Engaging (BiTE®) Antibody Constructs Efficiently Target Monocytic CD14 + hla-DR low IDO + aml-MDSCs

Dimitrios Mougiakakos, Domenica Saul, Martina Braun, Dr., Sehmus Tohumeken, Roman Kischel, MD, Lutteropp Michael, Dr., Cedric E. Dos Santos, Regina Jitschin, PhDMD, Andreas Mackensen, MD

Blood (2017) 130 (Supplement 1): 1363.

https://doi.org/10.1182/blood.V130.Suppl_1.1363.1363

Published: 2017

Journal Articles

Steroids Abrogate BiTE ® Antibody Construct-Mediated Cytotoxicity in Primary AML Cells

Christina Krupka, Bettina Lindl, Thomas Köhnke, MD, Julia Platzer, Lavinia Pachzelt, Felix S Lichtenegger, MD, Torben Altmann, Peter Kufer, MD, Roman Kischel, MD, Wolfgang Hiddemann, MD, PhD, Marion Subklewe, MD

Blood (2016) 128 (22): 3940.

https://doi.org/10.1182/blood.V128.22.3940.3940

Published: 2016

Journal Articles

Expression of Novel Immune Checkpoint Molecules PVR and PVRL2 Confers a Negative Prognosis to Patients with Acute Myeloid Leukemia and Their Blockade Augments T-Cell Mediated Lysis of AML Cells Alone or in Combination with the BiTE ® Antibody Construct AMG 330

Hauke Stamm, MSc, Felix Klingler, cand. MD, Daniela Pende, MD, Eik Vettorazzi, MSc, Michael Heuser, MD, Ulrike Mock, PhD, Carsten Bokemeyer, MD, Roman Kischel, MD, Sabine Stienen, PhD, Matthias Friedrich, PhD, Michael Lutteropp, PhD, Dirk Nagorsen, MD, Jasmin Wellbrock, PhD, Walter Fiedler, MD

Blood (2015) 126 (23): 789.

https://doi.org/10.1182/blood.V126.23.789.789

Published: 2015

Journal Articles

Identifying Immune Resistance Mechanisms to CD33/CD3 BiTE® Antibody Construct (AMG 330) Mediated Cytotoxicity

Christina Krupka, Thomas Köhnke, MD, Peter Kufer, Roman Kischel, Felix S. Lichtenegger, Franziska Brauneck, Stefan Rohling, Torben Altmann, Wolfgang Hiddemann, MD PhD, Marion S. Subklewe, MD

Blood (2015) 126 (23): 3677.

https://doi.org/10.1182/blood.V126.23.3677.3677

Published: 2015

Journal Articles

The Broad Activity of the CD33/CD3 Bispecific BiTE® Antibody AMG 330 in Primary Human AML Is Impacted By Disease Stage and Cytogenetic/Molecular Risk

Kimberly H. Harrington, BS, Chelsea J. Gudgeon, BS, George S. Laszlo, PhD, Kathryn J. Newhall, PhD, Angus M. Sinclair, PhD, Stanley R. Frankel, MD, Roman Kischel, MD, Guang Chen, PhD, Roland B. Walter, MD PhD MS

Blood (2014) 124 (21): 266.

https://doi.org/10.1182/blood.V124.21.266.266

Published: 2014

Journal Articles

Hydroxyurea Is Most Suitable for Cytoreduction of AML Prior to CD33/CD3 Bispecific BiTE® Antibody (AMG 330) Therapy: Uncompromised T-Cell Proliferation Ex-Vivo and CD33 Upregulation on AML Cells

Christina Krupka, Franziska Brauneck, Felix S Lichtenegger, MD, Peter Kufer, MD, Roman Kischel, MD, Gerhard Zugmaier, Thomas Köhnke, MD, Torben Altmann, MD, Stephanie Schneider, PhD, Michael Fiegl, MD, Karsten Spiekermann, MD, Angus M Sinclair, PhD, Kathryn J Newhall, PhD, Stanley R Frankel, MD, Patrick Baeuerle, PhD, Wolfgang Hiddemann, MD, Gert Riethmüller, MD, Marion Subklewe, MD

Blood (2014) 124 (21): 986.

https://doi.org/10.1182/blood.V124.21.986.986

Published: 2014

Journal Articles

PD-1/PD-L1 Blocking Enhances CD33/CD3-Bispecific BiTE® Antibody (AMG 330) Mediated Lysis of Primary AML Cells

Christina Krupka, Peter Kufer, MD, Roman Kischel, MD, Gerhard Zugmaier, Thomas Köhnke, MD, Felix S Lichtenegger, MD, Frauke M Schnorfeil, PhD, Torben Altmann, MD, Stephanie Schneider, PhD, Michael Fiegl, MD, Karsten Spiekermann, MD, Angus M Sinclair, PhD, Kathryn J Newhall, PhD, Stanley R Frankel, MD, Patrick Baeuerle, PhD, Wolfgang Hiddemann, MD, Gert Riethmüller, MD, Marion Subklewe, MD

Blood (2014) 124 (21): 3738.

https://doi.org/10.1182/blood.V124.21.3738.3738

Published: 2014

Journal Articles

Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML

George S. Laszlo, Chelsea J. Gudgeon, Kimberly H. Harrington, Justine Dell’Aringa, Kathryn J. Newhall, Gary D. Means, Angus M. Sinclair, Roman Kischel, Stanley R. Frankel, Roland B. Walter

Blood (2014) 123 (4): 554–561.

https://doi.org/10.1182/blood-2013-09-527044

Published: 2014

Includes: Supplemental data

NARROW

The Battle within: AML´s p53 Strategies to Evade T-Cell Attack

Sting Activation Improves T-Cell Engaging Immunotherapy of Acute Myeloid Leukemia

T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals

Treatment-Free Intervals during CD19xCD3 BiTE ® Construct-Mediated T-Cell Stimulation Induce Functional Reinvigoration and Transcriptional Reprogramming of Exhausted T Cells

CD33 BiTE ® Construct Mediated Immunological Synapse Formation and Downstream Signaling in T Cells Is Dependent on Expression of Costimulatory Molecules on Target Cells

Evolving Exhaustion of T Cells during the Course of the Disease in AML Can be Abrogated By CD33 BiTE ® Construct Mediated Cytotoxicity

Treatment-Free Intervals Mitigate T-Cell Exhaustion Induced By Continuous CD19xCD3-BiTE® Construct Stimulation in Vitro

Predictors of Efficacy for Blinatumomab in BCP-ALL Patients: Non-Responders Show Impaired CD19-BiTE®-Mediated Cytotoxicity in Vitro

Impact of p53 Knock-Down on T-Cell Proliferation and T-Cell Mediated Cytotoxicity Against AML Cell Lines Mediated By a CD33 Specific BiTE ® Antibody Construct

The Ratio of Costimulatory Vs Coinhibitory Molecules on AML Cells Determines the CD33-BiTE ® Mediated T-Cell Response

Midostaurin Reduces Bite® Mediated Cytotoxicity Against Acute Myeloid Leukemia

Generation of a Half-Life Extended Anti-CD19 BiTE ® Antibody Construct Compatible with Once-Weekly Dosing for Treatment of CD19-Positive Malignancies

CD33/CD3-Bispecific T-Cell Engaging (BiTE®) Antibody Constructs Efficiently Target Monocytic CD14 + hla-DR low IDO + aml-MDSCs

Steroids Abrogate BiTE ® Antibody Construct-Mediated Cytotoxicity in Primary AML Cells

Expression of Novel Immune Checkpoint Molecules PVR and PVRL2 Confers a Negative Prognosis to Patients with Acute Myeloid Leukemia and Their Blockade Augments T-Cell Mediated Lysis of AML Cells Alone or in Combination with the BiTE ® Antibody Construct AMG 330

Identifying Immune Resistance Mechanisms to CD33/CD3 BiTE® Antibody Construct (AMG 330) Mediated Cytotoxicity

The Broad Activity of the CD33/CD3 Bispecific BiTE® Antibody AMG 330 in Primary Human AML Is Impacted By Disease Stage and Cytogenetic/Molecular Risk

Hydroxyurea Is Most Suitable for Cytoreduction of AML Prior to CD33/CD3 Bispecific BiTE® Antibody (AMG 330) Therapy: Uncompromised T-Cell Proliferation Ex-Vivo and CD33 Upregulation on AML Cells

PD-1/PD-L1 Blocking Enhances CD33/CD3-Bispecific BiTE® Antibody (AMG 330) Mediated Lysis of Primary AML Cells

Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only